Can Basilea’s Antibiotic Succeed Where Others Have Failed?
Company Looks To Partner Ceftobiprole Ahead Of US Approval
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.
You may also be interested in...
The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.
Companies that are successful do not need to change their name, therapeutic area or product focus.
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.